A Phase 3 interventional study of IgPro20 in Primary Immunodeficiency (PID), sponsored by CSL Behring. Completed at 13 sites in 8 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-04-02.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2008, is one of 9 in phase 3, and was the 7th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 25 across the 13 interventional studies, 27 across the 1 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a continuation of the study ZLB06_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).
Biological: IgPro20
Also known as: IgG with Proline (IgPro), Hizentra
Total Serum IgG Trough Levels
The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.
Time frame: Up to 42 months
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs)
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by the Medical Monitor and Investigator to determine if the event fulfilled the predefined criteria for SBIs.
Time frame: Up to 42 months
Annualized Rate of Infection Episodes
The annualized rate was based on the total number of infection episodes occurring during the study divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: Up to 42 months
Number of Infection Episodes
Total number of infections for the specified analysis population
Time frame: Up to 42 months
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections
The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: Up to 42 months
Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections
Total number of days out of work / school / kindergarten / day care or unable to perform normal activities due to infections, for the specified analysis population
Time frame: Up to 42 months
Annualized Rate of Hospitalization Due to Infections
The annualized rate was based on the total number of days of hospitalization due to infections and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: Up to 42 months
Number of Days of Hospitalization Due to Infections
Total number of days of hospitalization due to infections for the specified analysis population
Time frame: Up to 42 months
Use of Antibiotics for Infection Prophylaxis and Treatment
Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.
Time frame: Up to 42 months
Health Related Quality of Life (Short Form 36 Health Survey)
The Short Form 36 Health Survey (SF-36) is a 36-item questionnaire that measures generic health concepts that are relevant across age, disease, and treatment groups. The questions are grouped into eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100, with higher scores indicating a better health state.
Time frame: At baseline and at the last available post-baseline observation for each subject (up to 42 months)
Clinically Relevant Changes in Vital Signs From Baseline to the Completion Visit.
The total number of subjects with clinically relevant changes in vital signs from baseline to the completion visit. Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, and body temperature.
Time frame: At baseline (data either from Infusion 40 or the completion visit of study ZLB06_001CR), and at completion (up to 42 months).
Clinically Significant Abnormal Changes in Routine Laboratory Parameters Between Baseline and the Completion Visit.
The total number of subjects with clinically significant abnormal changes in routine laboratory parameters between baseline and the completion visit. Routine laboratory parameters included haematology, serum chemistry and urinalysis.
Time frame: At baseline (data either from Infusion 40 or the completion visit of study ZLB06_001CR), and at completion (up to 42 months).
Rate, Severity and Relatedness of Any Adverse Events (AEs) Per Infusion
The rate of AEs was the number of AEs over the number of infusions administered. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Time frame: Up to 42 months
Subjects who had previously participated in the pivotal study ZLB06_001CR (NCT00542997) were enrolled in the extension study ZLB07_002CR.
| Milestone | IgPro20 |
|---|---|
| Started | 40 |
| Completed | 36 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Subject moved to another country | 1 |
| Withdrew: Poor adherence to asthma treatment | 1 |
The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.
| g/L | IgPro20 |
|---|---|
| Total Serum IgG Trough Levels | 7.97 ± 1.171 |
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by the Medical Monitor and Investigator to determine if the event fulfilled the predefined criteria for SBIs.
| SBIs per subject year | IgPro20 |
|---|---|
| Annualized Rate | 0.048 |
| Upper 1-sided 99% Confidence Limit | 0.1252 |
The annualized rate was based on the total number of infection episodes occurring during the study divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
| infection episodes per subject year | IgPro20 |
|---|---|
| Annualized Rate of Infection Episodes | 3.334 (2.993 to 3.703) |
Total number of infections for the specified analysis population
| infection episodes | IgPro20 |
|---|---|
| Number of Infection Episodes | 349 |
The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections | 6.773 |
Total number of days out of work / school / kindergarten / day care or unable to perform normal activities due to infections, for the specified analysis population
| days | IgPro20 |
|---|---|
| Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Activities Due to Infections | 706 |
The annualized rate was based on the total number of days of hospitalization due to infections and the total number of subject diary days for all subjects in the specified analysis population and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Annualized Rate of Hospitalization Due to Infections | 1.055 |
Total number of days of hospitalization due to infections for the specified analysis population
| days | IgPro20 |
|---|---|
| Number of Days of Hospitalization Due to Infections | 110 |
Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Use of Antibiotics for Infection Prophylaxis and Treatment | 72.13 |
The Short Form 36 Health Survey (SF-36) is a 36-item questionnaire that measures generic health concepts that are relevant across age, disease, and treatment groups. The questions are grouped into eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100, with higher scores indicating a better health state.
| score on a scale | IgPro20 - At Baseline | IgPro20 - At End of Study |
|---|---|---|
| Physical Functioning | 95.0 (75.0 to 100.0) | 100.0 (20.0 to 100.0) |
| Role-physical | 100.0 (18.8 to 100.0) | 100.0 (37.5 to 100.0) |
| Role-emotional | 100.0 (25.0 to 100.0) | 100.0 (25.0 to 100.0) |
| Social Functioning | 100.0 (62.5 to 100.0) | 100.0 (37.5 to 100.0) |
| Bodily Pain | 84.0 (22.0 to 100.0) | 84.0 (22.0 to 100.0) |
| Mental Health | 85.0 (55.0 to 95.0) | 80.0 (35.0 to 95.0) |
| Vitality | 65.6 (31.3 to 81.3) | 75.0 (18.8 to 100.0) |
| General Health | 52.0 (15.0 to 82.0) | 54.5 (20.0 to 92.0) |
The total number of subjects with clinically relevant changes in vital signs from baseline to the completion visit. Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, and body temperature.
| participants | IgPro20 |
|---|---|
| Clinically Relevant Changes in Vital Signs From Baseline to the Completion Visit. | 0 |
The total number of subjects with clinically significant abnormal changes in routine laboratory parameters between baseline and the completion visit. Routine laboratory parameters included haematology, serum chemistry and urinalysis.
| participants | IgPro20 |
|---|---|
| Haematology | 3 |
| Serum Chemistry | 1 |
| Urinalysis | 0 |
The rate of AEs was the number of AEs over the number of infusions administered. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
| AEs per infusion | IgPro20 |
|---|---|
| Total AEs | 0.0936 |
| Mild AEs | 0.0685 |
| Moderate AEs | 0.0231 |
| Severe AEs | 0.0020 |
| At least possibly related AEs | 0.0026 |
| Serious AEs | 0.0033 |
| At least possibly related and serious AEs | 0 |
Collected over AEs were collected for the duration of the study, up to 42 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro20 | — | 14/40 (35%) | 39/40 (97.5%) |
| Event | IgPro20 |
|---|---|
| Pneumonia bacterialInfections and infestations | 5/40 |
| ConcussionInjury, poisoning and procedural complications | 1/40 |
| Spinal column injuryInjury, poisoning and procedural complications | 1/40 |
| Abdominal painGastrointestinal disorders | 1/40 |
| FractureInjury, poisoning and procedural complications | 1/40 |
| Coeliac diseaseGastrointestinal disorders | 1/40 |
| DiarrhoeaGastrointestinal disorders | 1/40 |
| Thrombocytopenic purpuraBlood and lymphatic system disorders | 1/40 |
| PneumoniaInfections and infestations | 1/40 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/40 |
| Event | IgPro20 |
|---|---|
| BronchitisInfections and infestations | 21/40 |
| Upper respiratory tract infectionInfections and infestations | 18/40 |
| SinusitisInfections and infestations | 13/40 |
| NasopharyngitisInfections and infestations | 12/40 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/40 |
| RhinitisInfections and infestations | 9/40 |
| Febrile infectionInfections and infestations | 6/40 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/40 |
| Acute sinusitisInfections and infestations | 5/40 |
| PharyngitisInfections and infestations | 5/40 |
| Age, Customized(participants) | IgPro20 |
|---|---|
| 2 to < 12 years | 15 |
| 12 to < 16 years | 4 |
| 16 to < 65 years | 21 |
| ≥ 65 years | 0 |
| Sex: Female, Male(Participants) | IgPro20 |
|---|---|
| Female | 12 |
| Male | 28 |
The record gives a start of Aug 2008, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hizentra
Primary Immunodeficiency Diseases →